CVM: CEL-SCI Corp.
About
CEL-SCI Corp. is a biotechnology company, which engages in the research, development and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
Current Value
$0.601 Year Return
Current Value
$0.601 Year Return
Key Details
Market Cap
$38.57M
P/E Ratio
-1.07
1Y Stock Return
-74.28%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
3.9
Strategies that include CVM
Stock's related to CVM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EYPT | 46.39% | $446.88M | +39.17% | 0.00% |
| QXO | 37.28% | $6.81B | -33.42% | 0.00% |
| GRAL | 33.34% | $508.58M | -3.65% | 0.00% |
| CVGW | 32.08% | $483.31M | +12.94% | 1.84% |
| SAIC | 31.81% | $6.18B | +7.29% | 1.18% |
| WS | 31.10% | $2.23B | +75.80% | 1.08% |
| YMAB | 27.17% | $452.37M | +85.32% | 0.00% |
| CRBU | 26.41% | $179.29M | -65.20% | 0.00% |
| KALU | 26.33% | $1.31B | +35.91% | 3.78% |
| ROKU | 25.85% | $9.97B | -27.54% | 0.00% |
| ATRO | 25.44% | $604.40M | +11.37% | 0.00% |
| FARO | 25.37% | $497.53M | +43.95% | 0.00% |
| RUN | 25.01% | $2.29B | -10.43% | 0.00% |
| FUN | 24.88% | $4.54B | -17.47% | 0.00% |
| YELP | 24.86% | $2.34B | -22.21% | 0.00% |
| STOK | 24.84% | $596.94M | +190.46% | 0.00% |
| RLJ | 24.43% | $1.50B | -5.77% | 4.56% |
| AMWL | 24.42% | $122.71M | -66.06% | 0.00% |
| KRG | 24.35% | $5.97B | +31.93% | 3.69% |
| NWBI | 24.30% | $1.86B | +32.52% | 5.43% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BBW | 0.02% | $496.10M | +39.60% | 1.63% |
| ACGL | 0.02% | $37.09B | +20.63% | 0.00% |
| DRVN | -0.03% | $2.64B | +21.97% | 0.00% |
| X | 0.03% | $9.12B | +16.74% | 0.51% |
| UAN | -0.04% | $756.99M | +1.42% | 9.36% |
| WTW | 0.04% | $31.64B | +28.51% | 1.10% |
| GOOS | 0.05% | $962.92M | -10.71% | 0.00% |
| ACIU | 0.05% | $327.95M | +8.58% | 0.00% |
| NERV | -0.06% | $15.46M | -55.98% | 0.00% |
| OCSL | -0.06% | - | - | 14.14% |
| VZ | -0.06% | $178.91B | +13.79% | 6.27% |
| ORGO | -0.06% | $532.96M | +55.21% | 0.00% |
| WRB | 0.06% | $23.68B | +34.33% | 0.68% |
| SBSI | 0.07% | $1.06B | +25.02% | 5.08% |
| GLAD | -0.07% | - | - | 6.19% |
| FAX | -0.07% | - | - | 4.89% |
| IBCP | -0.09% | $788.13M | +75.44% | 2.51% |
| OBDC | -0.09% | $5.88B | +4.14% | 10.21% |
| GD | -0.09% | $76.97B | +13.18% | 1.98% |
| BTO | 0.09% | $3.75B | -5.92% | 5.61% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALK | -16.65% | $6.64B | +41.62% | 0.00% |
| AJX | -14.77% | $136.26M | -35.06% | 9.36% |
| RJF | -14.31% | $33.30B | +56.13% | 1.10% |
| TH | -13.92% | $867.71M | -20.27% | 0.00% |
| PULM | -13.82% | $22.32M | +230.27% | 0.00% |
| RVMD | -13.67% | $9.55B | +164.83% | 0.00% |
| KD | -13.65% | $7.55B | +79.01% | 0.00% |
| NOK | -13.15% | $22.52B | +17.00% | 3.36% |
| SCHW | -12.81% | $143.80B | +44.47% | 1.23% |
| LTM | -12.48% | $8.37B | -100.00% | <0.01% |
| GNK | -11.42% | $715.34M | +13.81% | 10.27% |
| LNG | -11.30% | $50.48B | +26.56% | 0.81% |
| SEG | -11.15% | $344.46M | +21.11% | 0.00% |
| RDDT | -10.57% | $27.74B | +364.76% | 0.00% |
| LPX | -9.61% | $8.04B | +86.84% | 0.91% |
| BSM | -9.50% | $3.23B | -12.29% | 10.44% |
| EG | -9.18% | $16.55B | -5.60% | 1.93% |
| PRPO | -9.14% | $8.89M | -14.59% | 0.00% |
| CMRE | -8.92% | $1.68B | +49.10% | 3.24% |
| ORLY | -8.83% | $69.55B | +21.51% | 0.00% |
ETF's related to CVM
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SRET | 24.70% | $214.09M | 0.59% |
| FINX | 24.60% | $338.80M | 0.68% |
| PINK | 24.59% | $163.05M | 0.5% |
| XHE | 24.24% | $215.46M | 0.35% |
| JEPI | 24.06% | $36.93B | 0.35% |
| PTH | 23.99% | $141.72M | 0.6% |
| XBI | 23.31% | $6.75B | 0.35% |
| EDOC | 22.85% | $41.83M | 0.68% |
| ARKG | 22.44% | $1.14B | 0.75% |
| IZRL | 22.39% | $104.51M | 0.49% |
| PEJ | 22.28% | $258.23M | 0.57% |
| ROBT | 22.25% | $449.25M | 0.65% |
| IMCG | 22.24% | $2.46B | 0.06% |
| VB | 22.22% | $64.38B | 0.05% |
| FVAL | 22.22% | $944.74M | 0.15% |
| GNOM | 22.21% | $71.22M | 0.5% |
| ERTH | 22.21% | $157.76M | 0.67% |
| PFUT | 22.16% | $322.01M | 0.64% |
| VXF | 22.11% | $21.85B | 0.06% |
| FTQI | 22.06% | $498.86M | 0.75% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TDTT | -0.08% | $1.86B | 0.18% |
| KRBN | 0.09% | $243.28M | 0.85% |
| GSY | 0.11% | $2.28B | 0.23% |
| COMT | 0.19% | $842.63M | 0.48% |
| AGGH | 0.27% | $255.41M | 0.33% |
| UTWO | -0.30% | $442.66M | 0.15% |
| HIGH | -0.33% | $301.36M | 0.51% |
| PREF | -0.34% | $1.01B | 0.55% |
| CORN | -0.35% | $61.32M | 0.2% |
| FMB | -0.38% | $2.03B | 0.65% |
| GSG | -0.39% | $935.59M | 0.75% |
| CGSM | -0.40% | $519.62M | 0.25% |
| FMHI | 0.63% | $753.14M | 0.7% |
| IBTH | 0.65% | $1.08B | 0.07% |
| IBTG | 0.66% | $1.49B | 0.07% |
| DFSD | -0.69% | $3.62B | 0.16% |
| IBDT | 0.74% | $2.37B | 0.1% |
| SHY | -0.89% | $22.50B | 0.15% |
| ULST | 0.91% | $535.66M | 0.2% |
| ICSH | 0.94% | $5.55B | 0.08% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -15.92% | $379.51M | 1.43% |
| TPMN | -14.44% | $40.73M | 0.65% |
| SEIX | -12.44% | $267.58M | 0.62% |
| BSJO | -9.35% | $452.72M | 0.43% |
| FLRT | -8.91% | $403.38M | 0.6% |
| CLOI | -8.85% | $720.91M | 0.4% |
| SHV | -8.81% | $18.36B | 0.15% |
| UUP | -8.54% | $359.07M | 0.77% |
| VRIG | -8.44% | $1.09B | 0.3% |
| TAIL | -8.38% | $68.06M | 0.59% |
| JBBB | -8.02% | $1.27B | 0.49% |
| IVOL | -8.01% | $549.88M | 1.02% |
| IBDQ | -7.81% | $2.90B | 0.1% |
| IGBH | -7.77% | $93.80M | 0.14% |
| SMB | -7.74% | $266.92M | 0.07% |
| KMLM | -7.67% | $348.59M | 0.9% |
| TBIL | -7.49% | $4.39B | 0.15% |
| FLBL | -7.40% | $647.33M | 0.45% |
| XHLF | -7.16% | $883.02M | 0.03% |
| XBIL | -6.97% | $637.84M | 0.15% |
News
SeekingAlpha
Discover new investment insights and recommendations from 42 new analysts on Seeking Alpha.
Yahoo
VIENNA, Va., November 07, 2024--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.
Finnhub
CEL-SCI Corporation today announced the potential positive impact on the clinical development of its immunotherapy Multikine resulting from a recent U.S. Food and Drug Administration Oncologic...
Yahoo
VIENNA, Va., October 22, 2024--FDA’s ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.
Finnhub
CEL-SCI Corporation today announced its renewed collaboration with Ergomed Clinical Research for its upcoming U.S. Food and Drug Administration confirmatory Registration Study of Multikine in head...
Yahoo
VIENNA, Va., October 01, 2024--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.